Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Log in

Definition and Terminology of Pediatric Chronic Myeloid Leukemia

https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Definition and Terminology of Pediatric Chronic Myeloid Leukemia
Полный текст Full text  

PDF (RUS)

PDF (RUS)
Abstract About the authors References

Abstract

Introduction. Chronic myeloid leukemia (CML) in children and adolescents is a rare malignant pathology of the hematopoietic system, accounting for only about 1-2% of oncohematological diseases, which determines the relevance of its study. The aim of the study is to identify characteristics of the terminology of chronic myeloid leukemia based on literature analysis. Materials and methods. The study materials were retrospective data obtained from searching the electronic databases PubMed, Medline, and Cochrane over the past 25 years. A total of 30 publications were analyzed, of which 10 met the inclusion criteria and were used for the review. Results and discussion. The term "childhood" CML reflects not only the age of patients with a BCR-ABL1-positive variant of the disease, but also specific biological characteristics, the frequency of which decreases with age. In addition, differences in prognostic criteria and treatment features in children and adults have been identified, which require consideration when choosing treatment tactics. Conclusion. The terminological and clinical specificity of CML in children emphasizes the need for further research and development of optimal approaches to the management of this group of patients.

About the authors

Аманкулова Айтбу Амануловна, кандидат медицинских наук, врач гематолог, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Макимбетов Эмил Кожошович, доктор медицинских наук, зав. каф. онкологии Кыргызско-Российского Славянского Университета имени первого Президента Российской Федерации Б.Н. Ельцина, Бишкек, Кыргызская Республика

Amankulova Aitbu Amanulovna,Candidate of Medical Sciences, hematologist, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Makimbetov Emil Kozhoshovich, Doctor of Medical Sciences, Head of the Department of Oncology, Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin, Bishkek, Kyrgyz Republic

Аманкулова Айтбу Амануловна, медицина илимдеринин кандидаты, Улуттук онкология жана гематология борборунун гематологу, Бишкек, Кыргыз Республикасы

Макимбетов Эмил Кожошович, медицина илимдеринин доктору, Россия Федерациясынын биринчи президенти Б.Н. атындагы Кыргыз-Орус Славян университетинин онкология кафедрасынын башчысы. Ельцин, Бишкек, Кыргыз Республикасы

References

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.

Keywords
Children , Diagnosis , Chronic myeloid leukemia , Adolescents , Terminology , Tyrosine kinase inhibitors
Для цитирования

Аманкулова А.А., Макимбетов Э.К. Определение и терминология детского хронического миелолейкоза. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с.93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
For citation

Amankulova A. A., Makimbetov E. K. Definition and Termi nology of Pediatric Chronic Myeloid Leukemia. Scientific and practical journal “Health care of Kyrgyzstan” 2025, No. 3, p. 93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Цитата үчүн

Аманкулова А.А., Макимбетов Э.К. Балдардагы өнөкөт миелоиддик лейкоздун аныктамасы жана терминологиясы. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3 б. 93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Authors Amankulova A.A., Makimbetov E.K.
Link doi.org https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Pages 93-97
Keywords Children, Diagnosis, Chronic myeloid leukemia, Adolescents, Terminology, Tyrosine kinase inhibitors
Russian
Об авторах

Аманкулова Айтбу Амануловна, кандидат медицинских наук, врач гематолог, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Макимбетов Эмил Кожошович, доктор медицинских наук, зав. каф. онкологии Кыргызско-Российского Славянского Университета имени первого Президента Российской Федерации Б.Н. Ельцина, Бишкек, Кыргызская Республика
Полный текст

PDF (RUS)
Список литературы

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.

Для цитирования

Аманкулова А.А., Макимбетов Э.К. Определение и терминология детского хронического миелолейкоза. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с.93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
English
About authors

Amankulova Aitbu Amanulovna,Candidate of Medical Sciences, hematologist, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Makimbetov Emil Kozhoshovich, Doctor of Medical Sciences, Head of the Department of Oncology, Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin, Bishkek, Kyrgyz Republic
Full text

PDF (RUS)
References

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.
For citation

Amankulova A. A., Makimbetov E. K. Definition and Termi nology of Pediatric Chronic Myeloid Leukemia. Scientific and practical journal “Health care of Kyrgyzstan” 2025, No. 3, p. 93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Kyrgyz
Авторлор жөнүндө

Аманкулова Айтбу Амануловна, медицина илимдеринин кандидаты, Улуттук онкология жана гематология борборунун гематологу, Бишкек, Кыргыз Республикасы

Макимбетов Эмил Кожошович, медицина илимдеринин доктору, Россия Федерациясынын биринчи президенти Б.Н. атындагы Кыргыз-Орус Славян университетинин онкология кафедрасынын башчысы. Ельцин, Бишкек, Кыргыз Республикасы
Шилтемелер

1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.

3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.
Цитата үчүн

Аманкулова А.А., Макимбетов Э.К. Балдардагы өнөкөт миелоиддик лейкоздун аныктамасы жана терминологиясы. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3 б. 93-97. https://dx.doi.org/10.51350/zdravkg2025.3.9.14.93.97
Views: 134
Copyright MAXXmarketing GmbH
JoomShopping Download & Support